Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at Lifesci Capital raised their FY2025 earnings per share estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($2.50) for the year, up from their prior forecast of ($2.53). The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.
Several other brokerages also recently issued reports on DNTH. Guggenheim reissued a "buy" rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating for the company. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $52.14.
View Our Latest Research Report on DNTH
Dianthus Therapeutics Price Performance
Dianthus Therapeutics stock traded down $1.23 during mid-day trading on Friday, hitting $20.74. The company's stock had a trading volume of 269,726 shares, compared to its average volume of 237,512. The firm's 50 day moving average is $22.44 and its 200 day moving average is $24.76. The company has a market cap of $613.84 million, a PE ratio of -8.30 and a beta of 1.82. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in DNTH. TCG Crossover Management LLC acquired a new position in shares of Dianthus Therapeutics during the 4th quarter valued at about $32,735,000. Braidwell LP increased its holdings in shares of Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after acquiring an additional 712,902 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares during the last quarter. State Street Corp increased its holdings in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Finally, Octagon Capital Advisors LP increased its holdings in shares of Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after acquiring an additional 363,500 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
